{"Clinical Trial ID": "NCT00550771", "Intervention": ["INTERVENTION 1:", "A diet based on pegylated liposomal doxorubicin (PDP)", "PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30 to 90 minutes administered every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) administered once weekly for 4 cycles (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes administered every week for 12 weeks (4 cycles)", "INTERVENTION 2:", "Doxorubicin based diet", "Doxorubicin 60 mg/m^2 intravenous push (IV) + cyclophosphamide 600 mg/m^2 IV over 30 to 90 minutes administered every 21 days for 4 cycles (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) administered every week for 12 weeks (4 cycles)"], "Eligibility": ["Incorporation criteria:", "Subjects with positive HER2 breast carcinoma are eligible for study provided they meet the following criteria:", "Subjects must demonstrate their willingness and ability to participate in the study and to adhere to dose and visit schedules.", "The subjects must be female and must be >= 18 years of age.", "Subjects should have been diagnosed with operational adenocarcinoma, confirmed histologically, without clinical or radiological evidence of metastatic disease, but with high or intermediate risk tumour characteristics:", "T1-3, N1-2, M0 (T level [tumor involvement], N [lymph involvement], and M [matastases]) OR", "- Negative node AND at least one of the following:", "Tumour > 2 cm or", "Tumour > 1 cm and", "- Negative estrogen/progesterone receptor (ER/PR) or", "Category of malignancy 2-3 or", "Presence of peritumoral vascular invasion or", "Age < 35 years", "HER2-positive by fluorescence in situ hybridization (FISH) (with gene amplification) or 3+ using", "Immunohistochemistry", "Subjects should have a complete resection (R0) of the primary tumour and axillary lymph nodes (or should have negative sentinel nodes)", "At the base, left ventricular ejection fraction (LVEF) by multiple sheath scan or echocardiogram (MUGA) >=55 %", "\u2022 Easter Cooperative Oncology Group (ECOG) - performance status of 0-1", "Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN)", "Adequate renal function: creatinine clearance calculated >=50 ml/min", "adequate postoperative hepatic function with total bilirubin < upper limit of normal (ULN), alkaline phosphatase < 2.5 times ULN and aspartate aminotransferase (AST) < 1.5 times ULN", "The subjects must be free from any clinically relevant disease that, in the opinion of the Principal Investigator and/or the sponsor, would interfere with the conduct of the study or evaluation of the study.", "Subjects of childbearing potential (including women less than one year after menopause and who will be sexually active during the study) must agree to use a medically accepted contraceptive method, while receiving protocol-specified medications for 30 days (or local requirements) after the drug has been discontinued or be surgically sterilized prior to screening.", "Subjects must be able to give their informed consent in writing.", "- Exclusion criteria:", "The subject who meets one of the following exclusion criteria will be excluded from participation in the study:", "Clinical or radiological evidence of metastatic disease", "\u2022 Prior radiation therapy, chemotherapy or breast cancer biotherapy currently diagnosed prior to randomisation", "Clinically significant pericardial infusion", "A serious heart disease, including, but not limited to,", "Documented history of congestive heart failure", "\u2022 History of any form of cardiomyopathy or active treatment for any form of cardiomyopathy", "\u2022 History of documented angina or transmural myocardial infarction, or active angina requiring medication", "\u2022 Severe ventricular arrhythmias requiring medicines or implantable cardioverter-defibrillator (ICD), uncontrolled supraventricular arrhythmias", "Clinically significant valvular disease", "Poorly controlled hypertension (systolic blood pressure (PB) > 180 mmHg, diastolic PB > 100 mmHg)", "\u00b7 Sensory/motor neuropathy > grade 2 as defined by the National Cancer Institute - Common Toxicity Criteria (NCI-CTC)", "Pregnancy or intention to become pregnant during the study", "\u2022 Nursing (nursing) or intention to be a nurse during the study", "Any of the following clinical conditions:", "Chronic obstructive pulmonary diseases requiring chronic treatment", "Clinically significant active infections", "A history of a psychological illness of the state, preventing the subject from understanding the requirements of the study", "Unstable regulation of diabetes mellitus", "A situation or condition which, in the opinion of the investigator, may impede optimal participation in the study", "Is a member of staff, affiliated with or a member of the family of staff directly involved in this study", "\u2022 Use of any test product within 30 days of registration", "\u00b7 Participation in any other clinical interventional study involving a drug, device or biological product, which would not prevent the patient from participating in a QOL, questionnaire, blood sample or observational study.", "Allergy or sensitivity to the medicine or its excipients"], "Results": ["Performance measures:", "Number of participants who experienced cardiac events (level 1 or 2), or inability to administer trastuzumab during the 8 cycles of chemotherapy or according to packaging insertion for a total duration of 1 year", "Cardiac events defined as:", "Level 1: Cardiac death due to heart failure (HF), myocardial infarction or arrhythmia, or probable cardiac death defined as sudden, unexpected death within 24 hours of a given or probable heart event, or severe symptomatic HF, associated with a decrease in left ventricular ejection fraction (LVEF) by > 10 percentage points from baseline and 50% of EVEF", "Level 2: Asymptomatic or slightly symptomatic systolic failure of HF associated with a decrease in LVF by >10 percentage points from baseline and <50% of LVF; the decrease in LVF was to be confirmed within 3-4 weeks.", "Time frame: 8 chemotherapy cycles followed by one year of treatment with trastuzumab", "Results 1:", "- Arm/group title: Pegylated Liposomal Doxorubicin (PELD) diet", "Description of the arm/group: PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30 to 90 minutes administered every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) administered once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes administered every week for 12 weeks (4 courses)", "Total number of participants analysed: 120", "Type of measurement: Number", "Unit of measure: Participants 5", "Results 2:", "Title of the arm/group: Doxorubicin-based diet", "Description of the arm/group: doxorubicin 60 mg/m^2 intravenous push (IV) + cyclophosphamide 600 mg/m^2 IV over 30 to 90 minutes administered every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) administered every week for 12 weeks (4 courses)", "Total number of participants analysed: 59", "Type of measurement: Number", "Unit of measure: Participants 11"], "Adverse Events": ["Undesirable Events 1:", "Total: 20/120 (16.67 per cent)", "ANEMIA 1/120 (0.83%)", "NEUTROPENIA FEBRILE 5/120 (4.17 per cent)", "LEUKOPENIA 1/120 (0.83%)", "NEUTROPENIA 0/120 (0.00 %)", "- ATMOSPHERIC THROMBOSE 1/120 (0.83%)", "CARDIAC FAILURE 1/120 (0.83%)", "INCOMPETENCE OF MITRAL VALUE 0/120 (0.00 %)", "Myocardial INFARCTION 1/120 (0.83%)", "PLEUROPERICARDITIS 1/120 (0.83%)", "- ABDOMINAL PEACE 0/120 (0.00 %)", "SUPER OF THE ABDOMINAL PEACE 1/120 (0.83%)", "Adverse Events 2:", "Total: 7/59 (11.86 per cent)", "ANEMIA 1/59 (1.69%)", "NEUTROPENIA FEBRILE 4/59 (6.78%)", "LEUKOPENIA 0/59 (0.00 %)", "NEUTROPENIA 2/59 (3.39%)", "ATMOSPHERIC THROMBOSE 0/59 (0.00 %)", "CARDIAC FAILURE 1/59 (1.69%)", "INCOMPETENCE OF MITRAL VALUE 1/59 (1.69 %)", "Myocardial INFARCTION 0/59 (0.00 %)", "PLEUROPERICARDITIS 0/59 (0.00 %)", "ABDOMINAL PEACE 1/59 (1.69%)", "OVERVIEW OF ABDOMINAL PEACE 0/59 (0.00 %)"]}